NewAmsterdam Pharma Warrant
NAMSW
10 hedge funds and large institutions have $11.5M invested in NewAmsterdam Pharma Warrant in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
0.3% less ownership
Funds ownership: 1.74% → 1.45% (-0.3%)
9% less funds holding
Funds holding: 11 → 10 (-1)
28% less capital invested
Capital invested by funds: $15.9M → $11.5M (-$4.4M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TFM
TFC Financial Management
Boston,
Massachusetts
|
+$93.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
-$1.34M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$344K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FLSM
1
Frazier Life Sciences Management
Palo Alto,
California
| $4.36M | – | – | – |
|
|
RCM
2
RA Capital Management
Boston,
Massachusetts
| $2.91M | – | – | – |
|
|
AAA
3
Affinity Asset Advisors
New York
| $1.92M | – | – | – |
|
|
BCLSI
4
Bain Capital Life Sciences Investors
Boston,
Massachusetts
| $872K | – | – | – |
|
|
DM
5
Deerfield Management
New York
| $809K | – | – | – |
|
|
HF
6
HRT Financial
New York
| $286K | – | – | – |
|
|
LCM
7
Laurion Capital Management
New York
| $145K | – | – | – |
|
|
VI
8
Vestcor Inc
Fredericton,
New Brunswick, Canada
| $91K | – | – | – |
|
|
TFM
9
TFC Financial Management
Boston,
Massachusetts
| $87.2K | +$93.3K | +10,000 | New |
|
10
CIBC Private Wealth Group
Atlanta,
Georgia
| $10.3K | – | – | – |
|
|
GS
11
GTS Securities
New York
| – | -$1.34M | -121,150 | Closed |
|
|
MIM
12
Monashee Investment Management
Boston,
Massachusetts
| – | -$344K | -31,189 | Closed |
|
NAMSW Hedge Fund Activity: Q2 2024 in Review
10 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma Warrant (NAMSW) for Q2 2024, worth a combined $11.5M — down 28% from $15.9M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NAMSW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was TFC Financial Management, opening a new position worth an estimated $93.3K. The largest seller was GTS Securities, exiting entirely with an estimated $1.34M sold.
- 10 institutional investors held NewAmsterdam Pharma Warrant (NAMSW) as of Q2 2024, down from 11 in Q1 2024.
- Funds reported $11.5M of NewAmsterdam Pharma Warrant stock for Q2 2024, down 28% quarter-over-quarter.
- 1 fund opened new NewAmsterdam Pharma Warrant positions in Q2 2024 and 2 closed out, a net change of -1 holder.
- The largest NewAmsterdam Pharma Warrant buyer in Q2 2024 was TFC Financial Management, an estimated $93.3K added.
- The largest NewAmsterdam Pharma Warrant seller in Q2 2024 was GTS Securities, an estimated $1.34M sold.
Based on aggregated 13F filings for Q2 2024.